Jan. 20, 2022, 8:42 a.m. EST

NIH says Pfizer's Paxloid should be first treatment option for certain COVID-19 patients

The National Institutes of Health on Wednesday updated its COVID-19 treatment guidelines for patients with mild to moderate forms of COVID-19 who are at high risk for disease progression. The new guidelines now include the recently authorized antivirals developed by Pfizer Inc. (NYS:PFE) and Merck & Co. Inc. (NYS:MRK) /Ridgeback Biotherapeutics, note that GlaxoSmithKline (NYS:GSK) and Vir Biotechnology Inc.'s (NAS:VIR) sotrovimab is the only monoclonal antibody that is thought to be effective against omicron, and have added a three-day course of Gilead Sciences Inc.'s (NAS:GILD) Veklury as a treatment option. The panel suggests that clinicians first use Pfizer's Paxlovid, then sotrovimab, then Veklury, and the final option should be molnupiravir, which is the Merck/Ridgeback drug.

Link to MarketWatch's Slice.